尿酸降低疗法对痛风和高尿血症全因和心血管疾病特异性死亡率的影响:一个元分析
1Department of Rheumatology, Korea University Anam Hospital, Korea University College of Medicine, 73, Goryeodae-ro, Seongbuk-gu, 02841, Seoul, Korea (Republic of). lyhcgh@korea.ac.kr.
Zeitschrift fur Rheumatologie
|December 5, 2024
概括
尿酸降低疗法 (ULT) 在患有痛风或高尿血症的患者中显著降低了全因死亡率. 虽然ULT有利于整体存活率,但在本次元分析中,阿洛普林醇没有显著影响心血管疾病特异性死亡率.
科学领域:
- 风湿病学和临床药理学
- 心血管流行病学心血管流行病学
- 公共卫生和死亡率研究
背景情况:
- 痛风和高尿血症与增加的死亡风险有关,特别是由于心血管原因.
- 尿酸降低疗法 (ULT) 旨在降低血清尿酸水平,但其对长期生存的影响需要全面评估.
- 了解ULT对所有原因和心血管疾病 (CVD) 特定死亡率的差异影响对于患者管理至关重要.
研究的目的:
- 调查尿酸降低疗法 (ULT) 与所有原因和心血管疾病 (CVD) 特定死亡率在患有痛风或高尿血症的个体之间的关联.
- 综合现有文献的证据,量化这些患者群体中ULT使用相关的死亡风险.
主要方法:
- 进行了系统的元分析,包括11项比较研究,共38396名ULT用户和47530名对照.
- 在PubMed,Embase和Cochrane数据库中进行了文献搜索,以确定所有原因和CVD特定死亡率的相关危险比率 (HR).
- 使用统计分析来评估汇集的HRs及其对应的死亡结果的置信区间 (CI).
主要成果:
- 在患有痛风或高尿血症的患者中,ULT显著降低了全因死亡风险 (HR = 0.783,95% CI = 0.702-0.874).
- 无论是ULT (HR = 0.651) 还是allopurinol (HR = 0.836) 都与全因死亡率的降低有关.
- 在高尿血病患者中,ULT显著降低了心血管疾病特异性死亡率 (HR = 0.872),但在痛风患者中没有 (HR = 0.676).
结论:
- 尿酸降低疗法 (ULT) 在降低患有痛风或高尿血症的患者全因死亡率方面具有显著的益处.
- 在这次元分析中,常见的ULTallopurinol对心血管疾病特异性死亡率没有显著影响.
- 这些发现突显了ULT在提高高尿酸水平的特定患者群体的生存率方面的重大潜力.
相关概念视频
Antihypertensive Drugs: Action of Diuretics
618
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
618
Factors Affecting Renal Clearance: Renal Impairment
53
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
53
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
532
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
532
Phase II Reactions: Glucuronidation
287
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
287
Renal Failure: Dose Adjustments
63
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
63
Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172


